DE69412073D1 - Xanthinderivate als adenosin-a1 rezeptor antagonisten - Google Patents

Xanthinderivate als adenosin-a1 rezeptor antagonisten

Info

Publication number
DE69412073D1
DE69412073D1 DE69412073T DE69412073T DE69412073D1 DE 69412073 D1 DE69412073 D1 DE 69412073D1 DE 69412073 T DE69412073 T DE 69412073T DE 69412073 T DE69412073 T DE 69412073T DE 69412073 D1 DE69412073 D1 DE 69412073D1
Authority
DE
Germany
Prior art keywords
adenosine
pct
receptor antagonists
xanthine derivatives
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69412073T
Other languages
English (en)
Other versions
DE69412073T2 (de
Inventor
Janice Hitchcock
Stephen Sorenson
Mark Dudley
Norton Peet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69412073D1 publication Critical patent/DE69412073D1/de
Publication of DE69412073T2 publication Critical patent/DE69412073T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69412073T 1993-02-26 1994-01-27 Xanthinderivate als adenosin-a1 rezeptor antagonisten Expired - Fee Related DE69412073T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2350193A 1993-02-26 1993-02-26
PCT/US1994/001009 WO1994019349A1 (en) 1993-02-26 1994-01-27 Xanthine derivatives as adenosine a1 receptor antagonists

Publications (2)

Publication Number Publication Date
DE69412073D1 true DE69412073D1 (de) 1998-09-03
DE69412073T2 DE69412073T2 (de) 1999-02-18

Family

ID=21815459

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69412073T Expired - Fee Related DE69412073T2 (de) 1993-02-26 1994-01-27 Xanthinderivate als adenosin-a1 rezeptor antagonisten

Country Status (19)

Country Link
US (1) US5840729A (de)
EP (1) EP0686155B1 (de)
JP (1) JPH08512281A (de)
KR (1) KR100315898B1 (de)
CN (1) CN1041418C (de)
AT (1) ATE169019T1 (de)
AU (1) AU680241B2 (de)
CA (1) CA2155130C (de)
DE (1) DE69412073T2 (de)
DK (1) DK0686155T3 (de)
ES (1) ES2120025T3 (de)
HU (1) HUT72677A (de)
IL (1) IL108750A (de)
MX (1) MX9401406A (de)
NO (1) NO311920B1 (de)
NZ (1) NZ262984A (de)
TW (1) TW261532B (de)
WO (1) WO1994019349A1 (de)
ZA (1) ZA941176B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0972525A4 (de) * 1997-03-18 2000-11-29 Fujisawa Pharmaceutical Co Vorbeugende und heilende mittel gegen hyperphosphatämie
AR020590A1 (es) 1998-06-02 2002-05-22 Cadus Pharmaceutical Corp 7-diazapurina-n-6 sustituida, un metodo para su preparacion, composiciones farmaceuticas que la comprenden
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
AU2002360436A1 (en) 2001-11-30 2003-06-17 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
US6916804B2 (en) 2001-12-20 2005-07-12 Osi Pharmaceuticals, Inc. Pyrimidine A2b selective antagonist compounds, their synthesis and use
AU2003247374A1 (en) * 2002-05-15 2003-12-02 Genzyme Corporation Synthesis of 2-alkylcysteines, 2-(hydroxylated phenyl)-4-alkylthiazoline-4-carboxylic acids and derivatives thereof
WO2004086047A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1)
KR20060124615A (ko) * 2003-12-09 2006-12-05 교와 핫꼬 고교 가부시끼가이샤 고차 뇌기능 장애의 예방 및/또는 치료제
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
JPH0455150A (ja) * 1990-06-22 1992-02-21 Takata Kk 助手席用エアバッグ装置
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5087827A (en) * 1991-02-11 1992-02-11 Tektronix, Inc. Variable voltage transition circuit
US5208240A (en) * 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
AU680241B2 (en) 1997-07-24
HU9502495D0 (en) 1995-10-30
ES2120025T3 (es) 1998-10-16
KR100315898B1 (ko) 2002-02-28
MX9401406A (es) 1994-08-31
NO953353L (no) 1995-08-25
IL108750A0 (en) 1994-05-30
AU6296894A (en) 1994-09-14
IL108750A (en) 2000-09-28
DE69412073T2 (de) 1999-02-18
US5840729A (en) 1998-11-24
EP0686155B1 (de) 1998-07-29
TW261532B (de) 1995-11-01
CN1118599A (zh) 1996-03-13
NO311920B1 (no) 2002-02-18
ZA941176B (en) 1994-09-20
CA2155130C (en) 1994-09-01
WO1994019349A1 (en) 1994-09-01
JPH08512281A (ja) 1996-12-24
CA2155130A1 (en) 1994-09-01
CN1041418C (zh) 1998-12-30
NZ262984A (en) 1997-05-26
ATE169019T1 (de) 1998-08-15
NO953353D0 (no) 1995-08-25
HUT72677A (en) 1996-05-28
EP0686155A1 (de) 1995-12-13
DK0686155T3 (da) 1999-02-01

Similar Documents

Publication Publication Date Title
DE69327536D1 (de) Fibrinogenrezeptor-antagonisten
DE69622031D1 (de) INDOLDERIVATE ALS cGMP-PDE INHIBITOREN
DE69318854D1 (de) Spiroazacyclischderivate als substanz p antagonisten
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
FI960727A (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
ES2121193T3 (es) Derivados de bencimidazoles.
DE69611377D1 (de) 1,2,4-triazolo[1,5-c]pyrimidin-heterocyclische analoge mit antagonistischer aktivität auf dem adenosine a2a rezeptor
DE69412073D1 (de) Xanthinderivate als adenosin-a1 rezeptor antagonisten
TR199900501T2 (xx) Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�.
ATE184008T1 (de) Pyrrolopyridinderivate als dopaminrezeptor liganden
DK0960111T3 (da) Morphinderivat med analgesisk aktivitet
IS1961B (is) Notkun 1-(2-naft-2-ýletýl)-4(3-tríflúorómetýlfenýl)-1,2,3,6-tetrahýdrópýridíns til gerðar lyfja tilþess að meðhöndla hliðarstrengjahersli
ATE189894T1 (de) Naphthamidderivate von 3-beta-amino azabicyclooctan oder nonan als antipsychotische arzneimittel
PL311296A1 (en) Derivatives of benzo [f] quinoxalinodione, method of obtaining them and their application in therapeutic agents
FR2695641B1 (fr) (Amino-3 phényl)-1 éthanesulfonate d'hydroquinine optiquement actif, sa préparation et son utilisation.
PT958290E (pt) Derivados de 1,4-di-hidropiridina e seu uso em terapia
ATE221068T1 (de) Anellierte beta-carboline

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee